US FDA delays decision on Moderna's Covid vaccine for adolescents: Report

The US health regulator is delaying its decision on authorizing Moderna Inc's COVID-19 vaccine for adolescents to check if the shot could increase the risk of a rare inflammatory heart condition, the Wall Street Journal reported on Friday.

Moderna shares fell nearly 4% to $319.50 in afternoon trading.

The U.S. Food and Drug Administration (FDA) has been inspecting the risk of the condition, myocarditis, among younger men vaccinated with Moderna's shot, especially versus Pfizer's vaccine, after certain Nordic countries limited use of the shot, the report said, citing people familiar with the matter.

The agency has not yet determined whether there is heightened